TransMolecular, Inc. Reports Positive Results from Phase 1 Trial ...
ASCO abstract re-confirms that intravenous radiolabeled TM601 can cross the blood-brain barrier and bind to tumor tissue-. CAMBRIDGE, MA – June 2, 2008 ...
http://www.biospace.com/news_story.aspx?NewsEntityId=98862...
|
Under Investigation: Using Bacteria and Scorpion Venom to Fight ...
June 9, 2005. Under Investigation: Using Bacteria and Scorpion Venom to Fight ... The 131I-TM-601 trial is a Phase II, 10-center study that will test a ...
http://www.slu.edu/readstory/more/5706...
|
TransMolecular, Inc. Presents Imaging and Pharmacokinetic Analysis ...
... Analysis of 131Iodine-TM601 at Society for Nuclear Medicine Meeting ... for Nuclear Medicine’s 55th Annual Meeting on June 16, 2008 by investigators at ...
http://www.biospace.com/news_story.aspx?NewsEntityId=100538...
|
ACS :: Research Milestones 2000-2007
2006 – In June, the FDA approves a new vaccine against the strains of the ... 2006 – TM-601, a drug derived from scorpion venom by former grantee Harald ...
http://www.cancer.org/docroot/RES/content/RES_1_1X_Research_...
|
BioSpace offers Pharmaceutical, Biotechnology and Healthcare ...
20 Jun 2007 ... Phase 1 Trial of 131Iodine-TM601 in Metastatic Melanoma 6/2/2008 More. ... June 4 At 9:00 A.M. EDT To Discuss Results 6/2/2008 More. ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...
|
#10-MAB W03
erability of a single dose of 131I-TM-601, as .... 2008, says Bolton. The school ’s typical ...... June 26, 2002. He was a resident of Birmingham, ...
http://www.uab.edu/uasom/alumni/mabwinter03.pdf...
|
